At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,613 enrolled
Drug / intervention
Aliskiren +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Eight Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension
In Brief
A Phase 3 clinical trial evaluating Aliskiren and Ramipril for Hypertension. Completed, enrolled 1,613 participants across 3 sites in 3 countries.
Detailed Summary
This study is designed to investigate the efficacy, safety and tolerability of aliskiren 300 mg, 150 mg and 75 mg when compared to ramipril 5 mg in patients with essential hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesChina, India, Thailand
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedSep 2007
Primary CompletionJul 2008
TodayJul 2026
First PostedSep 14, 2007
Enrollment StartSep 1, 2007
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.8 years ago
Interventions
Aliskirendrug
Aliskiren
Ramiprildrug
comparator